Human thymopoietin and splenin were isolated from human thymus and spleen, respectively, by monitoring tissue fractionation with a bovine thymopoietin RIA cross-reactive with human thymopoietin and splenin. Bovine thymopoietin and splenin are 49-amino acid polypeptides that differ by only 2 amino acids at positions 34 and 43; the change at position 34 in the active-site region changes the receptor specificities and biological activities. The complete amino acid sequences of purified human thymopoietin and splenin were determined and shown to be 48-amino acid polypeptides differing at four positions. Ten amino acids, constant within each species for thymopoietin and splenin, differ between the
human and bovine polypeptides. The pentapeptide active site of thymopoietin (residues 32-36) is constant between the human and bovine thymopoietins, but position 34 in the active site of splenin has changed from glutamic acid in bovine splenin to alanine in human splenin, accounting for the biological activity of the human but not the bovine splenin on the human T-cell line Thymopoietin (TP) is a polypeptide hormone of the thymus with pleiotropic actions on prothymocytes, mature T cells, the nicotinic acetylcholine receptor, and pituitary corticotrophs (1) (2) (3) (4) (5) (6) (7) (8) . The complete 49-amino acid sequence ofbovine TP (bTP) has been determined (9) , and the biological activity has been shown to reside in the pentapeptide Arg-Lys-AspVal-Tyr corresponding to residues 32-36 [TP-(32-36) pentapeptide, named thymopentin (TP-5)] (10). Antisera to bTP were developed and used to demonstrate TP in epithelial cells of the thymus and also in basal keratinocytes of skin (11, 12) . A RIA for bTP was developed (13, 14) , and this detected immunoreactive material in extracts of bovine spleen or lymph node in addition to thymus (9) . The immunoreactive substance in bovine spleen [bovine splenin (bSP)] was isolated using the bTP RIA to monitor purification; the complete amino acid sequence of bSP was determined (9) . The amino acid sequence of bSP differed from that of bTP by only two residues, this similarity accounting for their both reacting with anti-bTP antibodies. Like bTP, the active site of bSP was shown to reside in residues 32-36 (Arg-Lys-Glu-Val-Tyr, named splenopentin), the change in residue 34 accounting for the changes in biological activities between the two molecules (15) .
The RIA for bTP also detects immunoreactive material in extracts of human thymus and spleen. Therefore, we used this RIA to monitor the purification of the immunorcactive material in extracts of human thymus and spleen. We now report the isolation of these polypeptides and the determination of their complete amino acid sequences.
MATERIALS AND METHODS
Materials. Human thymus obtained from pediatric surgical specimens and human spleen from surgical or autopsy specimens were trimmed and stored at -35°C. Separation materials and apparatus were purchased commercially: Sephadex (Pharmacia), hydroxyapatite (Bio-Gel HTP; Bio-Rad), and preparative large-pore anion-exchange column (2.5 x 25 cm; DE 500, particle size 40-60 ,um) for HPLC (Separation Industries, Metuchen, NJ).
RIA of hTP and Human SP (hSP). The purification of hTP and hSP was monitored by using a RIA for bTP that was cross-reactive with hTP and hSP (13, 14) . Briefly, bTP was labeled with 125I by the Bolton-Hunter method (16) , and the radiolabeled bTP was purified as described (17) . Anti-bTP antibody (diluted 1:10,000) and 125I-labeled bTP (10,000 cpm), in the presence or absence of various peptide fractions in phosphate buffer, were incubated for 8 hr at 22°C. Separation of bound and free bTP was with 24% polyethylene glycol at room temperature, followed by centrifugation at 700 X g for 15 min. The bound bTP was assayed in a LKB y spectrometer. Isolation of hTP and hSP from Tissue Extracts. A 714-g batch of human thymus or 9000-g batch of human spleen was extracted in ice-cold 100 mM ammonium bicarbonate [25% (wet weight) containing 50 ng of 2-mercaptoethanol, 175 jig of phenylmethylsulfonyl fluoride, and 375 jig of EDTA per ml) by homogenizatiQn in a Waring Blendor (Dynamics, New Hartford, CT). After centrifugation at 14,000 x g for 10 min at 4°C, the supernatant was filtered through cheese cloth and stored at 4°C after addition of 0.1% thimerosal and 0.1% sodium azide. For thymus, the soluble extract was processed by ultrafiltration at 4°C using Amicon Diaflo membrane XM100 (molecular exclusion limit -Mr 100,000) and concentrated with Diaflo UM2 (molecular exclusion limit = Mr 1000), reducing the volume to 1/10th to 1/50th. For spleen, the extract was processed through an Amicon hollow fiber cartridge 1-Ox 100, followed 'by concentration on a Diaflo YM2 membrane in a thin-channel ultrafiltration system. Scheme 1 summarizes the isolation procedures. The retentate of the UM2 or YM2 filtration was chromatographed on bead-type Sephadex G-75 (particle size, 40-120 ,Am) at room temperature on a 5 x 150 cm column in 50 mM ammonium bicarbonate. Immunoreactive fractions were lyophilized. Two major peaks containing immunoreactive material were found for both thymus and spleen (Fig. 1) Table 1 ). This product had one major band and few minor bands on isoelectric gel focusing. The isoelectric point of the major band was 6.1 ± 0.2.
Amino Acid Composition. The amino acid composition is shown in Table 2 .
Cyanogen Bromide Cleavage and Separation of Fragments. Cyanogen bromide cleavage of hTP produced three distinct fractions ( Fig. 2A) , and the amino acid sequence results for each are summarized in Table 3 .
Structural Determination of hTP. Automated N-terminal sequencing of 240 pmol of hTP through 46 cycles of the Edman degradation gave a repetitive yield (average yield per cycle) of 93.4% and identified each of the 46 N-terminal residues (Fig. 3A) . The timed release of amino acids from the C terminus of intact hTP with carboxypeptidase Y (Table 4) provided an unequivocal C-terminal tetrapeptide sequence with a two-amino acid overlap (residues 45 and 46) with the N-terminal sequence. Partial sequence of hTP was confirmed by the structure determination of CNBr fragment I ( Fig. 2A) , which encompassed residues 32-40 and which includes the active site. In addition, the amino acid composition of intact hTP ( Table 2 .
Cyanogen Bromide Cleavage and Separation of Fragments. CNBr cleavage of the hSP produced three peaks (Fig.  2B) . The amino acid sequence and results for each are summarized in Table 3 .
Tryptic Digestion of Maleated hSP and Separation of Fragments. Maleated tryptic digestion of hSP produced five distinct peaks on HPLC (Fig. 4) . The sequence regions of peptide in each peak are summarized in Table 3 .
Structural Determination of hSP. hSP (110 pmol) was subjected to automated gas-phase sequence analysis by Edman degradation, and continuous identifications were made through the N-terminal 34 residues. The average yield per cycle was 90.2%, and the measured recoveries of selected residues are shown in Fig. 3B . The C-terminal sequence (Table 4 ) of the intact protein was determined with carboxypeptidase Y giving time-dependent release of amino acids. The C-terminal sequence of -Ala-Glu-His-COOH-provided a two-amino acid sequence overlap with the sequence of peak II obtained from a tryptic digest of maleated hSP (Fig. 4) . consistent with the N-terminal sequence determinations and the sequence completion by carboxypeptidase analysis. DISCUSSION We had previously used the cross-reactivity of anti-bTP antibodies to detect and isolate the closely related polypeptide bSP from bovine spleen (9) . Similarly, antibodies to bTP proved cross-reactive with hTP and hSP, and the bTP RIA was used to monitor the isolation of hTP and hSP from extracts of human thymus and spleen, respectively. Both isolations involved tissue extraction in aqueous solvent, ultrafiltration for approximate sizing and concentration, gel filtration for more accurate sizing, hydrophobic chromatography, and reverse-phase HPLC' (for hTP) or anion-exchange FPLC (for hSP). Approximately 50% of the immunoreactive material in each extract was present in a higher molecular weight form that probably represents a biologically inactive precursor form (21) . This was separated during molecular sieving on Sephadex G-75.
Despite simplification of the isolation procedure, the recovery of hTP was very low (0.42%), the purified material representing a 207-fold purification (Table 1) . Large losses of hTP occurred during' JIPLC, but for splenin, preparative FPLC was substituted for HPLLC, and the yield of 4.5% (1800-fold purification) ( Table 4) to the yields for bSP (9) . Purity of hTP and hSP was established by polyacrylamide gel electrophoresis, HPLC, and amino acid sequence (see below). For hTP, residues 1-46 were determined by automated Edman degradation with a gas-phase sequencer, and residues 1-11 and 32-46 were confirmed by Edman degradation of two CNBr-cleavage fragments. This provided independent confirmation of the important active-site region, residues 32-36.
The C-terminal sequence 44-48 was determined by timerelease carboxypeptidase digestion.
For hSP, residues 1-34 were determined by automated Edman degradation with the gas-phase sequencer, with confirmation of residues 1-16 from a CNBr-cleavage fragment, and extension of sequence 32-39 was determined from the other CNBr-cleavage fragment. This provided independent confirmation of the active-site region of hSP, which is different from that of bSP and from those of both bTP and hTP. The remaining sequence was determined from Edman degradation of fragments produced by tryptic digestion of maleated hSP (residues 1-15, 8-20, 18-30 , and 37-47) and by time-release carboxypeptidase digestion (residues 45-48). Tryptic cleavage of maleated hSP yielded fragments that represented cleavages between residues 7-8 (-Pro-Ala-), [17] [18] (-Ser-Glu-), and 36-37 (-Tyr-Val-); there was no cleavage at the protected site 31-32 (-Met-Arg-). We are at a loss to explain these anomalous cleavages other than that (Fig. 5) . They were also similar to bTP and bSP, with 10 residues being similar between hTP and hSP but different from the common residues in bTP and bSP at these positions (Fig. 5) . These comparisons confirm that the amino acid sequences of hTP and hSP were indeed determined and indicate that gene conversion must have occurred during evolution to maintain the parallel sequence evolution of these two polypeptides within each species. Other important gene systems that utilize gene conversion include immunoglobulin (22) and the major histocompatibility complex (23) genes. Maintenance of parallel evolution of regions of TP and SP outside the active-site region (residues [32] [33] [34] [35] [36] implies that these C-and N-terminal regions of the molecule must also have an important function, with similar requirements for both TP and SP being maintained within each species.
Residues 32-36 of bTP are known to represent the active site, with the corresponding synthetic TP-(32-36) pentapeptide TP-5 having the biological activities of TP in animals and man (10, 15) . The present studies establish that the active site of hTP (residues 32-36) is identical with that of bTP, so that synthetic TP-5 (Arg-Lys-Asp-Val-Tyr) also represents the human active site. bSP differs from bTP by having a glutamic acid residue at position 34, in contrast to aspartic acid at this position in bTP, and this change confers contrasting biological activities on bSP and synthetic splenopentin or SP-5 (Arg-Lys-Glu-ValTyr) by comparison with bTP and TP-5. Interestingly, position 34 of hSP has an alanine at position 34, thus differing from bSP and TP. hSP differs in its biological activity from bSP in that hSP but not bSP induces elevation of intracellular cGMP in MOLT-4, a human T-cell line (B. Baker, G. I. Viamontes, T.A. and G.G., unpublished data). Therefore, it was predicted that the active site of hSP would have changed from that of bSP, and this is now confirmed directly from the amino acid sequence.
The isolation and amino acid sequence determination of hTP and hSP should contribute to the further understanding of these important immunoregulatory polypeptides in man.
